Lisa H Lancaster (Lisa Lancaster)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Systemic Sclerosis

Idiopathic Pulmonary Fibrosis

Top Venues

BMJ open respiratory research

Respirology (Carlton, Vic.)

The open respiratory medicine journal

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Martin R J Kolb, Stylianos E Orfanos, Christopher Lambers, Kevin R Flaherty, Alison Masters, Lisa H Lancaster, Adam Silverstein, Steven D Nathan
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. Advances in therapy 39 (9) (2022)
Lisa H Lancaster, Francesco Bonella, Yoshikazu Inoue, Vincent Cottin, James Siddall, Mark Small, Jonathan Langley
Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology (Carlton, Vic.) (2021)
Laurie D Snyder, Christopher L Mosher, Colin H Holtze, Lisa H Lancaster, Kevin R Flaherty, Imre Noth, Megan L Neely, Anne S Hellkamp, Shaun Bender, Craig S Conoscenti, Joao A de Andrade, Timothy Pm Whelan
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. BMJ open respiratory research 7 (1) (2021)
Lisa H Lancaster, Jonathan Goldin, Matthias Trampisch, Grace Hyun J Kim, Jonathan Ilowite, Lawrence Homik, David L Hotchkin, Mitchell Kaye, Christopher J Ryerson, Nesrin Mogulkoc, Craig S Conoscenti
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. The open respiratory medicine journal 14 (2020)
Lisa H Lancaster, Bruno Crestani, Paul Hernandez, Yoshikazu Inoue, Daniel Wachtlin, Lazaro Loaiza, Manuel Quaresma, Susanne Stowasser, Luca Richeldi
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ open respiratory research 6 (1) (2019)